Webinar by Andrew Bruening‐Wright, Ph.D.
ChanTest Corporation - 01-28-2011
Part 1 – ChanTest: background, the hERG assay, and the need for more thorough preclinical safety assessment.
Part 2 –Why so much “buzz” about stem cell derived human cardiomyocytes (SC‐hCMs)?
Methods and validation of the SC‐hCM system at ChanTest.
Part 3 –Two examples of the utility of SC‐hCMs for elucidating complex mechanisms of drug action